[1] 冯红云, 范燕, 吴桂芝, 等. 关于我国麦考酚类药品生殖毒性风险的分析及思考[J]. 中国药物警戒, 2017,14(9):534-544. [2] Montcuquet A, Collongues N, Papeix C, et al.Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-lgG,mog-lgG,and seronegative neuromyelitis optica spectrum disorders[J].Mult Scler, 2017, 23(10) :1377-1384. [3] Chen H, Qiu W, Zhang Q, et al.Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treat-ments for neuromyelitis optica and neuromyelitis optica spectrum disorder[J].Eur J Neurol, 2017, 24(1) :219-226. [4] 竟永华, 李行, 郭剑非. 美国FDA药物肝毒性监测和管理文件简析[J]. 中国药物警戒, 2006,3(6):325-328. [5] Yang Y, Wang CJ, Wang BJ, et al.Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder[J]. Journal of the Neurological Sciences,2018, 385(1):192-197. [6] 吴丽敏, 汪珍珍, 张海燕. 吗替麦考酚酯联合泼尼松治疗儿童紫癜性肾炎疗效观察[J]. 抗感染药学, 2015 ,12(6):1005-1007. [7] Jiao Y, Cui L, Zhang W, et al.Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study[J]. BMC Neurology, 2018, 18(1):47-54. [8] 黎磊石, 王海燕, 林善锬, 等. 吗替麦考酚酯治疗弥漫增生性狼疮性肾炎的多中心临床研究[J]. 中华内科杂志, 2002, 41(7 ):476-479. [9] Chalasani NP, Hayashi PH, Bonkovsky HL, et al.ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2014, 109(7): 950-966. |